Crinone is generally well tolerated. In clinical studies, the following adverse events have been reported during Crinone therapy. Most adverse events observed in clinical studies cannot be distinguished from the symptoms common in early pregnancy.
Abdominal pain, perineal pain, headache, constipation, diarrhoea, nausea, joint pain, depression, decreased libido, nervousness, somnolence, breast tenderness/pain, dyspaerunia, nocturia; allergy, bloating, cramps, fatigue, pain, dizziness, vomiting, genital moniliasis/pruritus, aggressive reactions, forgetfulness, vaginal dryness, cystitis, urinary tract infection, vaginal discharge.
The adverse reactions of Crinone are qualitatively identical to those described in the medical literature for natural progesterone, but their frequency appears to be lower. Most adverse events are mild and transient in nature, frequently resolving during continued exposure to Crinone.
In addition, intermenstrual bleeding (spotting), hypersensitivity reactions usually manifesting as skin rash, vaginal irritation and other mild application site reactions have been reported post-marketing. For adverse reactions identified during post-marketing surveillance, quantification of frequency has not been attempted, but it is most likely uncommon to very rare.